DOCSLIB.ORG

Halofenate Is a Selective Peroxisome Proliferator–Activated Receptor ␥ Modulator with Antidiabetic Activity Tamara Allen,1 Fang Zhang,2 Shonna A

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Halofenate Is a Selective Peroxisome Proliferator–Activated Receptor ␥ Modulator with Antidiabetic Activity Tamara Allen,1 Fang Zhang,2 Shonna A Original Article Halofenate Is a Selective Peroxisome Proliferator–Activated Receptor ␥ Modulator With Antidiabetic Activity Tamara Allen,1 Fang Zhang,2 Shonna A. Moodie,2 L. Edward Clemens,2 Aaron Smith,1 Francine Gregoire,2 Andrea Bell,2 George E.O. Muscat,1 and Thomas A. Gustafson2 Halofenate has been shown previously to lower triglycer- (1–4). Treatment of dyslipidemic type 2 diabetic patients ides in dyslipidemic subjects. In addition, significant de- also showed triglyceride lowering and, surprisingly, signif- creases in fasting plasma glucose were observed but only in icant reductions in plasma glucose and insulin (3). Subse- type 2 diabetic patients. We hypothesized that halofenate quent studies in diabetic patients confirmed the glucose- might be an insulin sensitizer, and we present data to and triglyceride-lowering effects of halofenate in combina- suggest that halofenate is a selective peroxisome prolifera- tion with oral hypoglycemic drugs and as monotherapy tor–activated receptor (PPAR)-␥ modulator (SPPAR␥M). We demonstrate that the circulating form of halofenate, (4–7). While the precise mechanism of halofenate’s poten- halofenic acid (HA), binds to and selectively modulates tiation of the glycemic effect of sulfonylureas was not PPAR-␥. Reporter assays show that HA is a partial PPAR-␥ understood, it was originally hypothesized that halofenate, agonist, which can antagonize the activity of the full ago- being highly plasma protein bound, might dislodge oral nist rosiglitazone. The data suggest that the partial ago- hypoglycemic compounds from serum binding proteins, nism of HA may be explained in part by effective thus increasing their efficacy (8). However, significant displacement of corepressors (N-CoR and SMRT) coupled decreases in glucose were also observed with halofenate with inefficient recruitment of coactivators (p300, CBP, monotherapy (5) showing that halofenate could function and TRAP 220). In human preadipocytes, HA displays weak independently of sulfonylureas. In analyzing these histor- adipogenic activity and antagonizes rosiglitazone-medi- ated adipogenic differentiation. Moreover, in 3T3-L1 adi- ical data, we noted that halofenate lowered glucose levels pocytes, HA selectively modulates the expression of in diabetic, but not normoglycemic, subjects and that the multiple PPAR-␥–responsive genes. Studies in the diabetic time course of the beneficial glycemic effects was similar ob/ob mouse demonstrate halofenate’s acute antidiabetic to that of the insulin-sensitizing thiazolidinediones (TZDs), properties. Longer-term studies in the obese Zucker (fa/ which possesses glucose- and insulin-lowering properties fa) rat demonstrate halofenate’s comparable insulin sensi- mediated via activation of peroxisome proliferator–acti- tization to rosiglitazone in the absence of body weight vated receptor (PPAR)-␥ (9). We hypothesized that the increases. Our data establish halofenate as a novel insulin-sensitizing effects of halofenate might similarly ␥ SPPAR M with promising therapeutic utility with the po- involve PPAR-␥; we carried out a series of experiments to tential for less weight gain. Diabetes 55:2523–2533, 2006 test this hypothesis. PPAR-␥ is a member of the NR1C subgroup, which includes PPAR-␣ and -␦. These receptors form het- erodimers with the retinoid X receptor and modulate the alofenate was tested clinically in the 1970s as a transcription of genes. PPAR-␥ is predominantly ex- hypolipidemic and hypouricemic agent. In sub- pressed in white and brown adipose tissue, with lower sequent investigator-led studies, halofenate expression in liver, muscle, and other tissues (10). PPAR-␥ Hwas shown to lower serum triglycerides and ligands include a surprisingly diverse set of natural ligands uric acid in patients with a variety of hyperlipidemias (11) such as linolenic, eicosapentaenoic, docohexaenoic, and arachidonic acid and synthetic ligands such as the TZDs, L-tyrosine–based compounds, several nonsteroidal From the 1Division of Molecular Genetics and Development, Institute for Molecular Bioscience, University of Queensland, St. Lucia, Australia; and the anti-inflammatory drugs, and a variety of new chemical 2Department of Biology, Metabolex, Hayward, California. classes (12,13). Originally identified as a regulator of Address correspondence and reprint requests to Thomas A. Gustafson, adipogenesis, PPAR-␥ was thought to mediate the actions Metabolex, 3876 Bay Center Pl., Hayward, CA 94545. E-mail: gus@ metabolex.com. of TZDs solely through its actions in adipose tissue. Received for publication 4 May 2006 and accepted in revised form 20 June However, subsequent studies utilizing tissue-specific 2006. PPAR-␥ gene knockouts have demonstrated a complex T.A., F.Z., and S.A.M. contributed equally to this work. ␥ Additional information for this article can be found in an online appendix at role for PPAR- in whole-body insulin sensitivity involving http://diabetes.diabetesjournals.org. multiple tissues, including liver and muscle (14–16). AUC, area under the curve; HA, halofenic acid; ID, interaction domain; Two TZDs, rosiglitazone and pioglitazone, are currently PPAR, peroxisome proliferator–activated receptor; SPPAR␥M, selective approved to treat type 2 diabetes. Despite their proven PPAR-␥ modulator; TZD, thiazolidinedione. DOI: 10.2337/db06-0618 efficacy, a number of deleterious side effects have been © 2006 by the American Diabetes Association. noted, including increased weight gain and edema (17). The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked “advertisement” in accordance Weight gain is likely due to both increased adiposity and with 18 U.S.C. Section 1734 solely to indicate this fact. fluid retention. Edema is particularly a problem in patients DIABETES, VOL. 55, SEPTEMBER 2006 2523 HALOFENATE IS A SELECTIVE PPAR-␥ MODULATOR who are also taking insulin or sulfonylureas, and TZD treatment has been linked to increased incidence of con- gestive heart failure (17,18). Accordingly, efforts have been mounted to generate novel PPAR-␥ modulators that retain the beneficial clinical effects while avoiding these side effects. A variety of new PPAR-␥ ligands that possess differential pharmacological affinities for PPAR-␥ and have been termed selective PPAR-␥ modulators (SPPAR␥Ms) have recently been reported (19). SPPAR␥Ms are believed to bind in distinct manners to the ligand binding pocket of PPAR-␥, leading to altered receptor conformational stabil- ity and resulting in distinct patterns of gene expression FIG. 1. Chemical structures of compounds. Halofenate (A) is a pro-drug (20–22). The molecular basis of this effect is thought to ester of HA (B). Halofenate is rapidly modified in vivo to HA, the involve differential cofactor displacement and recruitment circulating form of the drug. that regulates gene expression in a gene- and tissue- ␮ specific manner (23). Further characterization of (catalog no. AM-1; 100 nmol/l insulin and 1.0 mol/l dexamethasone) in the ␥ presence of 0.25 mmol/l isobutyl-methylxanthine and either rosiglitazone (1 SPPAR Ms will ideally yield agents for the treatment of ␮mol/l) or HA (100 or 200 ␮mol/l) for 3 days and then fed with adipocyte diabetes, which are as effective as current therapies but medium for additional 12 days. PPAR-␥–mediated ligand-induced differentia- reduce or eliminate the more deleterious side effects. This tion was assessed by Oil Red O staining and analysis of FABP4 gene study was initiated in an effort to elucidate the underlying expression by quantitative PCR. mechanism of the antidiabetic effects of halofenate. Our Quantitative fluorescent real-time PCR analysis. Total RNA was isolated data suggest that halofenate is a novel SPPAR␥M with using Trizol (InVitrogen). cDNA was synthesized and used for quantitative fluorescent real-time PCR amplification. Amplification of each target cDNA robust antidiabetic and insulin-sensitizing activity. Fur- was then performed with TaqMan PCR Reagent Kits according to the thermore, halofenate appears to enhance insulin sensitiv- manufacturer’s protocol using Assay-On-Demand (Applied Biosystems) as- ity in a manner that leads to less weight gain than the says. 36B4 RNA was used as the control. Data are expressed as the means Ϯ currently marketed compounds. SE. Statistical significance was determined using ANOVA. ob/ob mouse studies. Male 8-week-old ob/ob mice (Jackson Laboratories) were used. All animal procedures were approved by the local institutional animal care and use committee following guidelines issued by the U.S. RESEARCH DESIGNS AND METHODS Department of Agriculture Animal and Plant Health Inspection Services. Plasmids. pCMX-mouse PPAR-␥ and -␣ plasmids were gifts from R. Evans. Halofenate was formulated daily as a suspension by vortexing in a mixture of The ligand-binding domain of mouse PPAR-␥ (aa 174–475) and -␣ (aa 2% Tween 80 and 1.0% (wt/vol) methylcellulose. Vehicle and halofenate were 166–463) was generated by PCR and cloned into pGAL0. Full-length mouse administered by oral gavage. Blood samples were collected by tail nipping 3 h PPAR-␥ was generated by PCR and cloned into pVP16. The ligand-binding after dosing. Plasma glucose levels were measured using the method of domains for human PPAR-␣ (aa 166–469), -␦ (aa 135–442), and -␥ (aa 172– Trinder (Glucose Oxidase G7016, Peroxidase P8125; Sigma Chemical, St. 476) were generated by PCR and cloned into pFA-CMV plasmid (Stratagene). Louis, MO) and insulin by radioimmunoassay (Linco).
Load more

Recommended publications
  • Telmisartan Use in Rats with Preexisting Osteoporotics Bone
    Life Sciences 237 (2019) 116890 Contents lists available at ScienceDirect Life Sciences journal homepage: www.elsevier.com/locate/lifescie Telmisartan use in rats with preexisting osteoporotics bone disorders T increases bone microarchitecture alterations via PPARγ Antonio Marcos Birocalea, Antonio Ferreira de Melo Jr.b, Pollyana Peixotob, Phablo Wendell Costalonga Oliveirab, Leandro Dias Gonçalves Ruffonic, Liliam Masako Takayamad, Breno Valentim Nogueirae, Keico Okino Nonakac, ∗ Rosa Maria Rodrigues Pereirad, José Martins de Oliveira Jr.f, Nazaré Souza Bissolib, a Department of Health Integrated Education, Federal University of Espirito Santo, Vitória, ES, Brazil b Department of Physiological Sciences, Federal University of Espirito Santo, Vitória, ES, Brazil c Department of Physiological Sciences, Federal University of São Carlos, São Carlos, SP, Brazil d Department of Medical Clinic, Medicine College, University of São Paulo, São Paulo, SP, Brazil e Department of Morphology, Federal University of Espirito Santo, Vitoria, ES, Brazil f Laboratory of Applied Nuclear Physics, University of Sorocaba, Sorocaba, SP, Brazil ARTICLE INFO ABSTRACT Keywords: Aims: Telmisartan (TEL), an angiotensin II type I receptor blocker and PPARγ partial agonist, has been used for Telmisartan to treat hypertension. It is known that PPARγ activation induces bone loss. Therefore, we evaluate the effects of PPARγ telmisartan on PPARγ protein expression, biomechanics, density and bone microarchitecture of femurs and Hypertension lumbar vertebrae in SHR ovariectomized animals, a model of hypertension in which preexisting bone impair- Ovariectomy ment has been demonstrated. Bone Main methods: SHR females (3 months old) were distributed into four groups: sham (S), sham + TEL (ST), OVX (C) and OVX + TEL (CT). TEL (5 mg/kg/day) or vehicle were administered according to the groups.
    [Show full text]
  • Conditional Expression of Human Pparδ and a Dominant Negative Variant of Hpparδ in Vivo
    Hindawi Publishing Corporation PPAR Research Volume 2012, Article ID 216817, 12 pages doi:10.1155/2012/216817 Research Article Conditional Expression of Human PPARδ and a Dominant Negative Variant of hPPARδ In Vivo Larry G. Higgins,1 Wojciech G. Garbacz,1 Mattias C. U. Gustafsson,2 Sitheswaran Nainamalai,3 Peter R. Ashby,1 C. Roland Wolf,1 and Colin N. A. Palmer1 1 CRUK Molecular Pharmacology Unit, Medical Research Institute, University of Dundee, Ninewells Hospital and Medical School, Dundee DD1 9SY, UK 2 Department of Laboratory Medicine, Division of Medical Microbiology, Lund University, Solvegatan¨ 23, SE-223 62 Lund, Sweden 3 Division of Molecular Medicine, Medical Science Institute, College of Life Sciences, University of Dundee, Dundee DD1 4HN, UK Correspondence should be addressed to Colin N. A. Palmer, [email protected] Received 21 September 2011; Revised 7 December 2011; Accepted 20 December 2011 Academic Editor: James P. Hardwick Copyright © 2012 Larry G. Higgins et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The nuclear receptor, NR1C2 or peroxisome proliferator-activated receptor (PPAR)-δ, is ubiquitously expressed and important for placental development, fatty acid metabolism, wound healing, inflammation, and tumour development. PPARδ has been hypothesized to function as both a ligand activated transcription factor and a repressor of transcription in the absence of agonist. In this paper, treatment of mice conditionally expressing human PPARδ with GW501516 resulted in a marked loss in body weight that was not evident in nontransgenic animals or animals expressing a dominant negative derivative of PPARδ.
    [Show full text]
  • Development of Novel Synthetic Routes to the Epoxyketooctadecanoic Acids
    DEVELOPMENT OF NOVEL SYNTHETIC ROUTES TO THE EPOXYKETOOCTADECANOIC ACIDS (EKODES) AND THEIR BIOLOGICAL EVALUATION AS ACTIVATORS OF THE PPAR FAMILY OF NUCLEAR RECEPTORS By ROOZBEH ESKANDARI Submitted in partial fulfillment of the requirements for The Degree of Doctor of Philosophy Thesis Advisor: Gregory P. Tochtrop, Ph.D. Department of Chemistry CASE WESTERN RESERVE UNIVERSITY January, 2016 CASE WESTERN RESERVE UNIVERSITY SCHOOL OF GRADUATE STUDIES We hereby approve the thesis/dissertation of ROOZBEH ESKANDARI Candidate for the Ph.D degree *. (signed) Anthony J. Pearson, PhD (Chair of the committee) Gregory P. Tochtrop, PhD (Advisor) Michael G. Zagorski, PhD Blanton S. Tolbert, PhD Witold K. Surewicz, PhD (Department of Physiology and Biophysics) (date) 14th July, 2015 *We also certify that written approval has been obtained for any proprietary material contained therein. I dedicate this work to my sister Table of Contents Table of Contents ........................................................................................................................ i List of Tables .............................................................................................................................. vi List of Figures ........................................................................................................................... vii List of Schemes .......................................................................................................................... ix Acknowledgements ..................................................................................................................
    [Show full text]
  • Bezafibrate Improves Insulin Sensitivity and Metabolic Flexibility
    2540 Diabetes Volume 65, September 2016 Andras Franko,1,2,3 Peter Huypens,1,3 Susanne Neschen,1,3,4 Martin Irmler,1 Jan Rozman,1,3,4 Birgit Rathkolb,1,4,5 Frauke Neff,1,6 Cornelia Prehn,7 Guillaume Dubois,1 Martina Baumann,1 Rebecca Massinger,1 Daniel Gradinger,1,3 Gerhard K.H. Przemeck,1,3 Birgit Repp,8 Michaela Aichler,9 Annette Feuchtinger,9 Philipp Schommers,10,11 Oliver Stöhr,12 Carmen Sanchez-Lasheras,13 Jerzy Adamski,3,7,14 Andreas Peter,2,3,15 Holger Prokisch,8 Johannes Beckers,1,3,16 Axel K. Walch,9 Helmut Fuchs,1,3,4 Eckhard Wolf,5 Markus Schubert,12,17 Rudolf J. Wiesner,10,18,19 and Martin Hrabe de Angelis1,3,4,16 Bezafibrate Improves Insulin Sensitivity and Metabolic Flexibility in STZ-Induced Diabetic Mice Diabetes 2016;65:2540–2552 | DOI: 10.2337/db15-1670 Bezafibrate (BEZ), a pan activator of peroxisome pro- the expression of PPAR and insulin target gene liferator–activated receptors (PPARs), has been gener- transcripts was increased. Furthermore, BEZ-treated ally used to treat hyperlipidemia for decades. Clinical mice also exhibited improved metabolic flexibility as trials with type 2 diabetes patients indicated that BEZ well as an enhanced mitochondrial mass and func- also has beneficial effects on glucose metabolism, tion in the liver. Finally, we show that the number of although the underlying mechanisms of these effects pancreatic islets and the area of insulin-positive remain elusive. Even less is known about a potential cells tended to be higher in BEZ-treated mice.
    [Show full text]
  • Targeting Energy Expenditure—Drugs for Obesity Treatment
    pharmaceuticals Review Targeting Energy Expenditure—Drugs for Obesity Treatment Carlos M. Jimenez-Munoz 1 , Marta López 1 , Fernando Albericio 2,3,4,* and Kamil Makowski 2,3,* 1 School of Chemical Sciences and Engineering Yachay Tech University, San Miguel de Urcuquí 100119, Ecuador; [email protected] (C.M.J.-M.); [email protected] (M.L.) 2 Department of Surfactants and Biotechnology, Institute for Advanced Chemistry of Catalonia (IQAC-CSIC), 08034 Barcelona, Spain 3 CIBER-BBN, Networking Centre of Bioengineering, Biomaterials, and Nanomedicine, and Department of Organic Chemistry, University of Barcelona, 08028 Barcelona, Spain 4 School of Chemistry and Physics, University of KwaZulu-Natal, Durban 4001, South Africa * Correspondence: [email protected] (F.A.); [email protected] or [email protected] (K.M.) Abstract: Obesity and overweight are associated with lethal diseases. In this context, obese and overweight individuals infected by COVID-19 are at greater risk of dying. Obesity is treated by three main pharmaceutical approaches, namely suppressing appetite, reducing energy intake by impairing absorption, and increasing energy expenditure. Most compounds used for the latter were first envisaged for other medical uses. However, several candidates are now being developed explicitly for targeting obesity by increasing energy expenditure. This review analyzes the compounds that show anti-obesity activity exerted through the energy expenditure pathway. They are classified on the basis of their development status: FDA-approved, Withdrawn, Clinical Trials, and Under Citation: Jimenez-Munoz, C.M.; Development. The chemical nature, target, mechanisms of action, and description of the current López, M.; Albericio, F.; Makowski, K.
    [Show full text]
  • PPAR-Δ Is Repressed in Huntington's Disease, Is Required for Normal
    ARTICLES PPAR-δ is repressed in Huntington’s disease, is required for normal neuronal function and can be targeted therapeutically Audrey S Dickey1, Victor V Pineda2, Taiji Tsunemi1, Patrick P Liu3–5, Helen C Miranda1, Stephen K Gilmore-Hall1, Nicole Lomas1, Kunal R Sampat1, Anne Buttgereit1, Mark-Joseph Manalang Torres2, April L Flores1, Martin Arreola1, Nicolas Arbez6, Sergey S Akimov6, Terry Gaasterland5,7, Eduardo R Lazarowski8, Christopher A Ross6,9–11, Gene W Yeo3–5, Bryce L Sopher2, Gavin K Magnuson12, Anthony B Pinkerton12, Eliezer Masliah13,14 & Albert R La Spada1,3–5,14–16 Huntington’s disease (HD) is a progressive neurodegenerative disorder caused by a CAG trinucleotide repeat expansion in the huntingtin (HTT) gene, which encodes a polyglutamine tract in the HTT protein. We found that peroxisome proliferator-activated receptor delta (PPAR-) interacts with HTT and that mutant HTT represses PPAR-–mediated transactivation. Increased PPAR- transactivation ameliorated mitochondrial dysfunction and improved cell survival of neurons from mouse models of HD. Expression of dominant-negative PPAR- in the central nervous system of mice was sufficient to induce motor dysfunction, neurodegeneration, mitochondrial abnormalities and transcriptional alterations that recapitulated HD-like phenotypes. Expression of dominant-negative PPAR- specifically in the striatum of medium spiny neurons in mice yielded HD-like motor phenotypes, accompanied by striatal neuron loss. In mouse models of HD, pharmacologic activation of PPAR- using the agonist KD3010 improved motor function, reduced neurodegeneration and increased survival. PPAR- activation also reduced HTT-induced neurotoxicity in vitro and in medium spiny-like neurons generated from stem cells derived from individuals with HD, indicating that PPAR- activation may be beneficial in HD and related disorders.
    [Show full text]
  • Cross-Linking Cellular Prion Protein Induces Neuronal Type 2-Like Hypersensitivity
    ORIGINAL RESEARCH published: 30 July 2021 doi: 10.3389/fimmu.2021.639008 Cross-Linking Cellular Prion Protein Induces Neuronal Type 2-Like Hypersensitivity Utpal Kumar Adhikari 1, Elif Sakiz 1, Xian Zhou 2, Umma Habiba 1, Sachin Kumar 1, Meena Mikhael 1, Matteo Senesi 3,4, Chun Guang Li 2, Gilles J. Guillemin 5, Lezanne Ooi 6,7, Monique Antoinette David 1, Steven Collins 3,4, Tim Karl 1,8,9 and Mourad Tayebi 1* 1 School of Medicine, Western Sydney University, Campbelltown, NSW, Australia, 2 National Institute of Complementary Medicine (NICM) Health Research Institute, Western Sydney University, Campbelltown, NSW, Australia, 3 Australian National Creutzfeldt-Jakob Disease Registry, The Florey Institute of Neuroscience and Mental Health, The University of Melbourne, Parkville, VIC, Australia, 4 Department of Medicine, Royal Melbourne Hospital, The University of Melbourne, Parkville, VIC, Australia, 5 Department of Biomedical Sciences, Faculty of Medicine and Health Sciences, Macquarie University, Wollongong, NSW, Australia, 6 School of Chemistry and Molecular Bioscience, Illawarra Health and Medical Research Institute, Wollongong, NSW, Australia, 7 School of Chemistry and Molecular Bioscience, University of Wollongong, Wollongong, NSW, Australia, 8 Neuroscience Research Australia (NeuRA), Sydney, NSW, Australia, 9 School of Medical Sciences, University of Edited by: New South Wales, Sydney, NSW, Australia Giuseppe Legname, International School for Advanced Background: Previous reports identified proteins associated with ‘apoptosis’ following Studies (SISSA), Italy cross-linking PrPC with motif-specific anti-PrP antibodies in vivo and in vitro.The Reviewed by: Chih-Li Lin, molecular mechanisms underlying this IgG-mediated neurotoxicity and the role of the Chung Shan Medical University, activated proteins in the apoptotic pathways leading to neuronal death has not been Taiwan properly defined.
    [Show full text]
  • Peroxisome Proliferator-Activated Receptors and Their Novel Ligands As Candidates for the Treatment of Non-Alcoholic Fatty Liver Disease
    cells Review Peroxisome Proliferator-Activated Receptors and Their Novel Ligands as Candidates for the Treatment of Non-Alcoholic Fatty Liver Disease Anne Fougerat 1,*, Alexandra Montagner 1,2,3, Nicolas Loiseau 1 , Hervé Guillou 1 and Walter Wahli 1,4,5,* 1 Institut National de la Recherche Agronomique (INRAE), ToxAlim, UMR1331 Toulouse, France; [email protected] (A.M.); [email protected] (N.L.); [email protected] (H.G.) 2 Institut National de la Santé et de la Recherche Médicale (Inserm), Institute of Metabolic and Cardiovascular Diseases, UMR1048 Toulouse, France 3 Institute of Metabolic and Cardiovascular Diseases, University of Toulouse, UMR1048 Toulouse, France 4 Lee Kong Chian School of Medicine, Nanyang Technological University Singapore, Clinical Sciences Building, 11 Mandalay Road, Singapore 308232, Singapore 5 Center for Integrative Genomics, Université de Lausanne, Le Génopode, CH-1015 Lausanne, Switzerland * Correspondence: [email protected] (A.F.); [email protected] (W.W.); Tel.: +33-582066376 (A.F.); +41-79-6016832 (W.W.) Received: 29 May 2020; Accepted: 4 July 2020; Published: 8 July 2020 Abstract: Non-alcoholic fatty liver disease (NAFLD) is a major health issue worldwide, frequently associated with obesity and type 2 diabetes. Steatosis is the initial stage of the disease, which is characterized by lipid accumulation in hepatocytes, which can progress to non-alcoholic steatohepatitis (NASH) with inflammation and various levels of fibrosis that further increase the risk of developing cirrhosis and hepatocellular carcinoma. The pathogenesis of NAFLD is influenced by interactions between genetic and environmental factors and involves several biological processes in multiple organs. No effective therapy is currently available for the treatment of NAFLD.
    [Show full text]
  • Multiple Peroxisome Proliferator-Activated Receptor B Subtypes from Atlantic Salmon (Salmo Salar)
    391 Multiple peroxisome proliferator-activated receptor b subtypes from Atlantic salmon (Salmo salar) Michael J Leaver, M Tariq Ezaz, Stephanie Fontagne, Douglas R Tocher, Evridiki Boukouvala1 and Grigorios Krey1 Institute of Aquaculture, University of Stirling, Stirling FK9 4LA, UK 1National Agricultural Research Foundation, Fisheries Research Institute, Nea Peramos, 64007 Kavala, Greece (Requests for offprints should be addressed to M J Leaver; Email: [email protected]) (M Tariq Ezaz is now at Research School of Biological Sciences, Australian National University, Canberra, Australian Capital Territory 0200, Australia) (S Fontagne is now at INRA, 64310 Saint-Pee sur Nivelle, France) Abstract Peroxisome proliferator-activated receptors (PPARs) are ligand-activated transcription factors belonging to the nuclear hormone receptor superfamily that functions as critical regulators of lipid and energy homeostasis. Although intensively studied in mammals, their basic biological functions are still poorly understood. The objective of this work was to characterize PPARb subtypes in a fish, the Atlantic salmon (Salmo salar), in order to address PPAR function and the regulation of lipid homeostasis in lower vertebrates. The screening of an Atlantic salmon genomic library revealed the presence of four genes for PPARb subtypes. Based on comparisons of exons and exon-flanking regions, these genes were assigned into two families, ssPPARb1 and ssPPARb2, each family containing two isotypes: ssPPARb1A and b1B and ssPPARb2A and b2B. Two full-length cDNAs for ssPPARb1A and ssPPPARb2A were isolated. Transcripts for ssPPARb1A and ssPPARb2A have distinct tissue expression profiles, with ssPPARb1A predominating in liver and ssPPARb2A predominating in gill. Expression levels of mRNA of either isotypes were up to tenfold lower in kidney, heart, spleen, muscle, and brain.
    [Show full text]
  • Metabolic Switching of Human Skeletal Muscle Cells in Vitro
    View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by Open Digital Archive at Oslo and Akershus University College Metabolic switching of human skeletal muscle cells in vitro Thoresen GH1, Hessvik NP1, SS Bakke1, Aas V2 and Rustan AC1 1Department of Pharmaceutical Biosciences, School of Pharmacy, University of Oslo, Oslo, Norway 2Faculty of Health Sciences, Oslo University College, Oslo, Norway Correspondence to: AC Rustan, Department of Pharmaceutical Biosciences, School of Pharmacy, University of Oslo, P.O.Box 1068, Blindern 0316, Oslo, Norway e-mail: [email protected], phone: +4722856558, fax: +4722854402 Support: The present work was funded by University of Oslo, The European Nutrigenomics Organisation (NuGO), The Norwegian Diabetes Foundation, AstraZeneca, Freia Chocolade Fabriks Medical Foundation, and The Anders Jahre’s Foundation 1 Summary In this review we will focus on external factors that may modify energy metabolism in human skeletal muscle cells (myotubes) and the ability of the myotubes to switch between lipid and glucose oxidation. We describe the metabolic parameters suppressibility, adaptability and substrate-regulated flexibility and show the influence of nutrients such as fatty acids and glucose (chronic hyperglycemia), and some pharmacological agents modifying nuclear receptors (PPAR and LXR), on these parameters in human myotubes. Possible cellular mechanisms for changes in these parameters will also be highlighted. Metabolic flexibility Skeletal muscle is the main tissue involved in lipid and glucose oxidation in the body. In the postprandial state glucose oxidation dominates, however fat oxidation increases both during fasting and sustained exercise [1-3]. The ability to switch from predominantly lipid oxidation during fasting conditions to increased glucose oxidation and suppression of lipid oxidation in response to insulin [2, 3] is called metabolic flexibility, and is a characteristic of healthy skeletal muscle [4, 5].
    [Show full text]
  • GW501516-Activated Pparβ/Δ Promotes Liver Fibrosis Via P38-JNK
    Kostadinova et al. Cell & Bioscience 2012, 2:34 http://www.cellandbioscience.com/content/2/1/34 Cell & Bioscience RESEARCH Open Access GW501516-activated PPARβ/δ promotes liver fibrosis via p38-JNK MAPK-induced hepatic stellate cell proliferation Radina Kostadinova1,2, Alexandra Montagner1,3, Erwan Gouranton1, Sébastien Fleury4, Hervé Guillou3, David Dombrowicz4, Pierre Desreumaux5 and Walter Wahli1* Abstract Background: After liver injury, the repair process comprises activation and proliferation of hepatic stellate cells (HSCs), which produce extracellular matrix (ECM) proteins. Peroxisome proliferator-activated receptor beta/delta (PPARβ/δ) is highly expressed in these cells, but its function in liver repair remains incompletely understood. This study investigated whether activation of PPARβ/δ with the ligand GW501516 influenced the fibrotic response to injury from chronic carbon tetrachloride (CCl4) treatment in mice. Wild type and PPARβ/δ-null mice were treated with CCl4 alone or CCl4 co-administered with GW501516. To unveil mechanisms underlying the PPARβ/δ-dependent effects, we analyzed the proliferative response of human LX-2 HSCs to GW501516 in the presence or absence of PPARβ/δ. Results: We found that GW501516 treatment enhanced the fibrotic response. Compared to the other experimental groups, CCl4/GW501516-treated wild type mice exhibited increased expression of various profibrotic and pro-inflammatory genes, such as those involved in extracellular matrix deposition and macrophage recruitment. Importantly, compared to healthy liver, hepatic fibrotic tissues from alcoholic patients showed increased expression of several PPAR target genes, including phosphoinositide-dependent kinase-1, transforming growth factor beta-1, and monocyte chemoattractant protein-1. GW501516 stimulated HSC proliferation that caused enhanced fibrotic and inflammatory responses, by increasing the phosphorylation of p38 and c-Jun N-terminal kinases through the phosphoinositide-3 kinase/protein kinase-C alpha/beta mixed lineage kinase-3 pathway.
    [Show full text]
  • Rosiglitazone Activation of Pparg Suppresses Fractalkine Signaling
    135 Rosiglitazone activation of PPARg suppresses fractalkine signaling Yihong Wan1,2 and Ronald M Evans2 1Department of Pharmacology, University of Texas Southwestern Medical Center, 6001 Forest Park Road, Room ND8.502B, Dallas, Texas 75390-9041, USA 2Gene Expression Laboratory, Howard Hughes Medical Institute, Salk Institute for Biological Studies, La Jolla, California 92037, USA (Correspondence should be addressed to Y Wan; Email: [email protected]; R M Evans; Email: [email protected]) Abstract The nuclear receptor peroxisome proliferator-activated receptor g (PPARg) is a key transcriptional regulator of both lipid metabolism and inflammation. The importance of PPARg is accentuated by the widespread use of synthetic PPARg agonists, thiazolidinediones (such as rosiglitazone), as drugs for insulin resistance and type II diabetes. Fractalkine (FKN) and FKN receptor (FR) play an important role in the immune responses by regulating leukocyte migration and adhesion to inflamed peripheral tissues. In this study, we have identified a novel link between PPARg activation and FKN signaling. On one hand, the activation of PPARg by rosiglitazone in macrophages not only represses the transcription of the FR gene, but also prevents the plasma membrane translocation of the FR protein. On the other hand, the activation of PPARg by rosiglitazone in endothelial cells also impedes the nuclear export of FKN. Together, these data suggest that PPARg activation represses FKN signaling. These findings indicate a previously unrecognized mechanism that may contribute to the anti-inflammatory effect of PPARg. Journal of Molecular Endocrinology (2010) 44, 135–142 Introduction reported to increase the risk of AIDS and to reduce the risk of coronary artery disease (Faure et al.
    [Show full text]